Clinical Study On The Treatment Of Ankylosing Spondylitis With Kidney Four Taste Modified And Yisaipu

Objective:To compare the clinical efficacy and safety of Kidney Four Taste Modified with Yisaipu and Yisaipu in the treatment of ankylosing spondylitis(AS).To provide clinical research data for the treatment of AS by the combination of kidney four taste modified with Yisaipu,and to select effective programs for the treatment of AS by the combination of traditional Chinese and western medicine,to improve the clinical remission rate and quality of life of AS patients and obtain the maximum benefit/risk ratio.Methods:Total of 60 patients diagnosed with AS in the outpatient and ward of the department of rheumatology and immunology of Inner Mongolia armed police corps hospital and the hospital of traditional Chinese medicine of Inner Mongolia autonomous region from December 2017 to January 2019 were randomly divided into control group and experimental group.The experimental group was treated with yisaipu combined with four flavors of kidney,while the control group was treated with yisaipu.Continuous application for 24 weeks and observation records in general(age,gender,duration)and the baseline,treatment for 3 months,6 months of clinical observation index(refers to the distance,Schober test,BASDAI score,BASFI score,thoracic mobility,pain VAS score),laboratory indexes(Erythrocyte sedimentation rate(ESR),Hypersensitive c-reactive protein(CRP)),security index(blood routine,urine routine,liver function,kidney function,test for hepatitis B,mycobacterium tuberculosis T cell detection,Chest positive lateral slice)and adverse reactions,calculate ASAS20 success rate.Results:After 6 months of treatment,the mean distance,Schober test,chest activity,BASDAI score,BASFI score,pain VAS score,ESR and CRP of the two groups were significantly improved compared with the baseline of this group(P<0.05).Comparison results between the two groups:after 3 months of treatment,the comparison between the two groups of clinical observation indicators(mean distance,Schober test,chest activity,BASDAI score,BASFI score,pain VAS score)and laboratory indicators(ESR,CRP)showed that the experimental group was superior to the control group,and the difference was statistically significant(P<0.05).After 6 months of treatment,the comparison between the two groups of clinical observation indicators(mean distance,Schober test,chest activity,BASDAI score,BASFI score,pain VAS score)and laboratory indicators(ESR,CRP)showed that the experimental group was superior to the control group,and the difference was statistically significant(P<0.05).After 6 months of treatment,the ASAS20 compliance rate of the experimental group reached 83.33%,and that of the control group reached 53.33%.The improvement of the experimental group was more significant than that of the control group,and the difference between the two groups was statistically significant(P<0.05).In the clinical trial,no abnormal changes of the safety indicators were found in the regular review,and no serious adverse reactions occurred in the two groups during the treatment.Conclusion:(1)The treatment of AS with Kidney Four Taste Modified with Yisaipu can effectively improve the clinical symptoms and important signs of patients,improve the quality of life,and improve the inflammatory indicators.(2)The therapeutic effect of Kidney Four Taste Modified with Yisaipu in treating AS is better than that of Yisaipu alone.(3)There were no serious adverse reactions in the treatment of AS by Kidney Four Taste Modified with Yisaipu.